Program | Discovery | Lead Optimization | IND-Enabling | Phase 1 | Phase 2 | Phase 3 | Partner |
|---|---|---|---|---|---|---|---|
| PRA023 - Anti-TL1A mAb | |||||||
| PR600 - Anti-TNF Super Family Member mAb |  | ||||||
| PR300 - GPCR Modulator Small Molecule | |||||||
| TPR15 - mAb | Partnered  | ||||||
| Prometheus has an early-stage discovery collaboration with Takeda Pharmaceuticals. | ||||||
| Program | Progress |
|---|---|
| PRA023 | Phase 1 |
| PR600 | Discovery |
| PR300 | Discovery |
| TPR15 | Discovery |